These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 12126522

  • 1. [A randomized control trial of mycophenolate mofeil treatment in severe IgA nephropathy].
    Chen X, Chen P, Cai G, Wu J, Cui Y, Zhang Y, Liu S, Tang L.
    Zhonghua Yi Xue Za Zhi; 2002 Jun 25; 82(12):796-801. PubMed ID: 12126522
    [Abstract] [Full Text] [Related]

  • 2. Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial.
    Hou JH, Le WB, Chen N, Wang WM, Liu ZS, Liu D, Chen JH, Tian J, Fu P, Hu ZX, Zeng CH, Liang SS, Zhou ML, Zhang HT, Liu ZH.
    Am J Kidney Dis; 2017 Jun 25; 69(6):788-795. PubMed ID: 28215945
    [Abstract] [Full Text] [Related]

  • 3. Treatment of severe IgA nephropathy: mycophenolate mofetil/prednisone compared to cyclophosphamide/prednisone.
    Liu X, Dewei D, Sun S, Xu G, Liu H, He L, Zhang P.
    Int J Clin Pharmacol Ther; 2014 Feb 25; 52(2):95-102. PubMed ID: 24161158
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Retrospective study of mycophenolate mofetil treatment in IgA nephropathy with proliferative pathological phenotype.
    Liang Y, Zhang J, Liu D, Quan S, Xing G, Liu Z.
    Chin Med J (Engl); 2014 Feb 25; 127(1):102-8. PubMed ID: 24384432
    [Abstract] [Full Text] [Related]

  • 8. Long-term study of mycophenolate mofetil treatment in IgA nephropathy.
    Tang SC, Tang AW, Wong SS, Leung JC, Ho YW, Lai KN.
    Kidney Int; 2010 Mar 25; 77(6):543-9. PubMed ID: 20032964
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide.
    Branten AJ, du Buf-Vereijken PW, Vervloet M, Wetzels JF.
    Am J Kidney Dis; 2007 Aug 25; 50(2):248-56. PubMed ID: 17660026
    [Abstract] [Full Text] [Related]

  • 12. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study.
    Maes BD, Oyen R, Claes K, Evenepoel P, Kuypers D, Vanwalleghem J, Van Damme B, Vanrenterghem YF.
    Kidney Int; 2004 May 25; 65(5):1842-9. PubMed ID: 15086925
    [Abstract] [Full Text] [Related]

  • 13. Combination therapy with mycophenolate mofetil and prednisone in steroid-resistant idiopathic membranoproliferative glomerulonephritis.
    Yuan M, Zou J, Zhang X, Liu H, Teng J, Zhong Y, Ding X.
    Clin Nephrol; 2010 May 25; 73(5):354-9. PubMed ID: 20420795
    [Abstract] [Full Text] [Related]

  • 14. Mycophenolate mofetil treatment for therapy-resistant glomerulopathies.
    Sahin GM, Sahin S, Kantarci G, Ergin H.
    Nephrology (Carlton); 2007 Jun 25; 12(3):285-8. PubMed ID: 17498124
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of mycophenolate mofetil treatment in IgA nephropathy: a systematic review.
    Chen Y, Li Y, Yang S, Li Y, Liang M.
    BMC Nephrol; 2014 Dec 05; 15():193. PubMed ID: 25475967
    [Abstract] [Full Text] [Related]

  • 16. Effect of mycophenolate mofetil on kidney graft function and body weight in patients with chronic allograft nephropathy.
    Grebe SO, Mueller TF, Troeltsch M, Ebel H, Lange H.
    Transplant Proc; 2004 Dec 05; 36(10):2974-8. PubMed ID: 15686673
    [Abstract] [Full Text] [Related]

  • 17. Mycophenolate mofetil in the treatment of IgA nephropathy: a systematic review.
    Tan CH, Loh PT, Yang WS, Chan CM.
    Singapore Med J; 2008 Oct 05; 49(10):780-5. PubMed ID: 18946610
    [Abstract] [Full Text] [Related]

  • 18. [Mycophenolate mofetil in high risk IgA glomerulonephritis].
    Frutos MA, López V, Alférez MJ, Aranda P.
    Nefrologia; 2005 Oct 05; 25(4):387-92. PubMed ID: 16231504
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the therapeutic effects of leflunomide and mycophenolate mofetil in the treatment of immunoglobulin A nephropathy manifesting with nephrotic syndrome.
    Liu XW, Li DM, Xu GS, Sun SR.
    Int J Clin Pharmacol Ther; 2010 Aug 05; 48(8):509-13. PubMed ID: 20650041
    [Abstract] [Full Text] [Related]

  • 20. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial.
    Dussol B, Morange S, Burtey S, Indreies M, Cassuto E, Mourad G, Villar E, Pouteil-Noble C, Karaaslan H, Sichez H, Lasseur C, Delmas Y, Nogier MB, Fathallah M, Loundou A, Mayor V, Berland Y.
    Am J Kidney Dis; 2008 Oct 05; 52(4):699-705. PubMed ID: 18585835
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.